Aggrenox
AssetAlso called Asasantin, dipyridamole, acetylsalicylic acid, modified-release dipyridamole
Fixed combination of aspirin and dipyridamole acting as antiplatelet agents
- Stage
- Approved, not sold in the US
- Modality
- Small molecule
- Target
- SLC29A1
- 3
- Indications
- 9
- Trials
- 1
- Developer
Approved by the FDA on Nov 22, 1999 (NDA020884). Not sold in the US: Drugs@FDA marks every US product that holds it discontinued. FDA
Indications
3No named disease
Approved, not sold in the US, FDA, Nov 22, 1999
Stroke
Phase 3, Completed, NCT00153062, clinicaltrials.gov, Oct 31, 2026
Coronary artery disease
Phase 3, Completed, NCT00129038, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Target and mechanism25
- Owner and partners3
- Trials9
- Evidence for its targets8
- Competitors12
- Aging relevance1
- Signals12
Every asset’s record: target, stage, trials and the evidence behind it.